CC BY 4.0 · TH Open 2019; 03(02): e190-e199
DOI: 10.1055/s-0039-1688414
Original Article
Georg Thieme Verlag KG Stuttgart · New York

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries

Naresh Gupta
1   Department of Medicine and The Haemophilia Centre, Maulana Azad Medical College & Associated Lok Nayak and GB Pant Hospitals, New Delhi, India
,
Abderrahmane Benbouzid
2   Department of Orthopaedics, University Medical Centre of Ben Aknoun, Ben Aknoun, Algeria
,
Meriem Belhani
3   Department of Haematology, University Hospital of Beni Messous, Beni Messous, Algeria
,
Mohammed El Andaloussi
4   Paediatric Orthopaedic and Traumatology Service, Abderrahim Harouchi Hospital, Part of the Ibn Rochd University Hospital, Casablanca, Morocco
,
Khadija Maani
5   Department of Paediatrics, Haematology and Oncology Unit, Abderrahim Harouchi University Children's Hospital–Medical School of Casablanca, Casablanca, Morocco
,
Yasser Wali
6   Department of Child Health, Sultan Qaboos University, Muscat, Oman
7   Department of Paediatrics, Alexandria University, Alexandria, Egypt
,
Soraya Benchikh El Fegoun
8   Novo Nordisk Health Care AG, Zurich, Switzerland
,
Hossam Ali Saad
9   Novo Nordisk Inc., Plainsboro, New Jersey, United States
,
Johnny Mahlangu
10   Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Hospital, Department of Molecular Medicine and Haematology, National Health Laboratory Service and Faculty of the Health Sciences, University of Witwatersrand, Johannesburg, South Africa
› Institutsangaben
Weitere Informationen

Publikationsverlauf

24. Januar 2019

15. März 2019

Publikationsdatum:
27. Juni 2019 (online)

Abstract

Introduction Optimizing hemophilia care remains challenging in developing countries. Burden-of-disease studies are important to develop strategies for improving hemophilia care.

Aim The HAEMOcare study evaluated the factors contributing to hemophilia-related orthopedic disease burden in developing countries.

Methods HAEMOcare was a noninterventional, cross-sectional, epidemiological study conducted in Algeria, India, Morocco, Oman, and South Africa. Male patients with severe hemophilia (N = 282) aged ≥6 years, without or with inhibitors, being treated on-demand for bleeding were included. Hemophilia-related orthopedic clinical and functional status was assessed using the Hemophilia Joint Health Score (HJHS), radiological status with the Pettersson Score, and quality of life with the EuroQol five-dimension questionnaire (EQ-5D-3L). Direct and indirect economic costs of hemophilia care were also calculated.

Results Patients (mean [standard deviation, SD] age: 20.8 [10.6] years) experienced a mean annualized bleeding rate of 25.8. Overall mean (SD) HJHS and Pettersson score were 17.9 (12.8) and 15.0 (13.5), respectively; scores were similar between patients without or with inhibitors (p = 0.21 and 0.76, respectively). Approximately 70% of adults reported problems relating to pain/discomfort and mobility parameters in the EQ-5D-3L. Mean distance to a hemophilia treatment center (HTC) was 79.4 km. As expected, total costs of hemophilia were statistically significantly higher in patients with inhibitors versus without inhibitors (p = 0.002).

Conclusion Inadequate access to HTCs and expert care, along with high bleeding rates, led to equivalent hemophilia-related orthopedic morbidity between hemophilia patients without and with inhibitors. HAEMOcare documented the economic and disease burdens associated with suboptimal hemophilia care in developing countries.

Authors' Contributions

Naresh Gupta designed and performed the research, analyzed the data, and wrote and edited the manuscript. Abderrahmane Benbouzid performed the research and wrote and edited the manuscript. Meriem Belhani wrote and edited the manuscript. Mohammed El Andaloussi performed the research and wrote and edited the manuscript. Khadija Maani performed the research and wrote and edited the manuscript. Yasser Wali designed and performed the research, analyzed the data, and wrote and edited the manuscript. Soraya Benchikh El Fegoun designed the research, analyzed the data, and wrote and edited the manuscript. Hossam Ali Saad designed the research, analyzed the data, and wrote and edited the manuscript. Johnny Mahlangu designed and performed the research, analyzed the data, and wrote and edited the manuscript.


 
  • References

  • 1 Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007; 136 (06) 777-787
  • 2 Morfini M, Haya S, Tagariello G. , et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13 (05) 606-612
  • 3 Tusell JM, Aznar JA, Querol F, Quintana M, Moreno M, Gorina E. ; Orthopaedic Study Group. Results of an orthopaedic survey in young patients with severe haemophilia in Spain. Haemophilia 2002; 8 (Suppl. 02) 38-42
  • 4 Soucie JM, Cianfrini C, Janco RL. , et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103 (07) 2467-2473
  • 5 Windyga J, Stefańska E, Lopaciuk S, Juszyński A, Woźniak D, Strzelecki O. The orthopaedic status of a selected severe haemophilia group [in Polish]. Pol Arch Med Wewn 2005; 113 (06) 562-569
  • 6 Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl. 06) 20-22
  • 7 Stieltjes N, Torchet MF, Misrahi L. , et al. Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost—the “Statut Orthopédique des Patients Hémophiles” avec Inhibiteur study. Blood Coagul Fibrinolysis 2009; 20 (01) 4-11
  • 8 Ferreira AA, Leite IC, Bustamante-Teixeira MT, Guerra MR. Hemophilia A in Brazil—epidemiology and treatment developments. J Blood Med 2014; 5: 175-184
  • 9 Haghpanah S, Mohtadi H, Akbari M, Karimi M. Quality of life in children and adolescents with rare bleeding disorders in southern Iran. Clin Appl Thromb Hemost 2017; 23 (06) 652-656
  • 10 Berkouk-Redjimi Y, Ouarlent Y, Handi S. , et al. Orthopaedic status and surgical needs of patients with haemophilia in Algeria. Open J Hematol 2013; 4: 1
  • 11 The World Bank. Changes in country classifications. 2011 . Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/378832-what-is-the-world-bank-atlas-method . Accessed August 30, 2017
  • 12 Gupta N, Belhani M, Benbouzid A. , et al. The HAEMOcare protocol—a composite method to measure the disease burden from haemophilia in developing countries. Haematologica 2013; 98 (Suppl. 01) 436-437
  • 13 EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (03) 199-208
  • 14 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
  • 15 Molho P, Rolland N, Lebrun T. , et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia 2000; 6 (01) 23-32
  • 16 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (01) 25-32
  • 17 Bladen M, Main E, Hubert N, Koutoumanou E, Liesner R, Khair K. Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia. Haemophilia 2013; 19 (04) 626-631
  • 18 Manco-Johnson MJ, Abshire TC, Shapiro AD. , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
  • 19 Taki M, Shirahata A. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. Haemophilia 2009; 15 (01) 78-82
  • 20 Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD. ; Association of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC). The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14 (05) 923-930
  • 21 Fischer K, Astermark J, van der Bom JG. , et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8 (06) 753-760
  • 22 Kalnins W, Mondorf W. Self-assessment of health and social status with emphasis on orthopedic function. Paper presented at: 37th Haemophilia Symposium; 2006; Hamburg, Germany
  • 23 Berntorp E, Dolan G, Hay C. , et al. European retrospective study of real-life haemophilia treatment. Haemophilia 2017; 23 (01) 105-114
  • 24 Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49-56
  • 25 duTreil S. Physical and psychosocial challenges in adult hemophilia patients with inhibitors. J Blood Med 2014; 5: 115-122
  • 26 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
  • 27 World Federation of Hemophilia. World Federation of Hemophilia report on the Annual Global Survey 2013. Available at: http://www1.wfh.org/publications/files/pdf-1591.pdf . Accessed July 31, 2017
  • 28 World Federation of Hemophilia. World Federation of Hemophilia report on the Annual Global Survey 2015. Available at: http://www1.wfh.org/publications/files/pdf-1669.pdf . Accessed July 31, 2017